Press Releases 2013


 
2014 | 2013 | 2012 | 2011
DateTitle 
December 18, 2013Incyte to Present at the 32nd Annual J. P. Morgan Healthcare Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 18, 2013-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the 32nd Annual J. P. Morgan Healthcare Conference on Monday, January 13th at 8:30 a.m. (PST) / 11:30 a.m. (EST) in San Francisco. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available. Investors interested i... 
Printer Friendly Version
December 09, 2013Positive Results Presented from Proof-of-Concept Phase II Clinical Trial of Incyte's Oral JAK1 Inhibitor in Patients with Myelofibrosis
In data presented at the 2013 ASH Annual Meeting, treatment with two out of three trial doses of INCB39110 provided meaningful improvements in myelofibrosis related symptoms Data suggest JAK1 inhibition may result in less myelosuppression than use of JAK1/JAK2 inhibitors and JAK2 inhibitors NEW ORLEANS--(BUSINESS WIRE)--Dec. 9, 2013-- Incyte Corporation (Nasdaq: INCY) announced results of an interim analysis fro... 
Printer Friendly Version
December 09, 2013Jakafi® (ruxolitinib) Continues to Show Improved Overall Survival for Patients with Myelofibrosis in Further Analyses of Phase III Data Presented at 2013 ASH
Data from multiple presentations, including three-year follow-up analysis from COMFORT-I and a pooled analysis of the two COMFORT trials, suggest that patients treated with Jakafi maintained reductions in spleen volume and had improved survival over placebo and best available therapy A separate retrospective analysis suggests that Jakafi treatment may reduce the risk of death by approximately 50 percent compared to co... 
Printer Friendly Version
November 25, 2013Incyte to Present at the Oppenheimer 24th Annual Healthcare Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 25, 2013-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the Oppenheimer 24th Annual Healthcare Conference on Wednesday, December 11 at 10:40 a.m. (EST) in New York. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available. Investors interested in listening to the liv... 
Printer Friendly Version
November 14, 2013Incyte Completes Offering of $750 Million of Convertible Senior Notes
$500 million of offering proceeds used to repurchase existing convertible notes WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 14, 2013-- Incyte Corporation (Nasdaq: INCY) today announced that it has completed its previously announced private placement of $750 million aggregate principal amount of its convertible senior notes, including notes issued upon the exercise in full of the initial purchasers’ option to purchase additional notes. The Company ... 
Printer Friendly Version
November 07, 2013Incyte Prices Offering of $700 Million of Convertible Senior Notes
Notes offered in Two $350 Million Series, Due in 2018 and 2020 Up to $500 million of offering proceeds to be used for repurchase of existing convertible notes WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 7, 2013-- Incyte Corporation (Nasdaq:INCY) today announced the pricing of a total offering of $700 million aggregate principal amount of its convertible senior notes, consisting of $350 million aggregate principal amount of 0.375% convertib... 
Printer Friendly Version
November 06, 2013Incyte Announces Proposed Offering of $700 Million of Convertible Senior Notes
Notes to be offered in Two $350 Million Series, Due in 2018 and 2020 Up to $500 million of offering proceeds to be used for repurchase or retirement of existing convertible notes WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 6, 2013-- Incyte Corporation (Nasdaq: INCY) today announced its intention to offer, subject to market and other conditions, $350 million aggregate principal amount of convertible senior notes due 2018 and $350 million ag... 
Printer Friendly Version
October 31, 2013Incyte Reports Third-Quarter 2013 Financial Results; Updates Shareholders on Key Clinical Programs
$60.2 million of third-quarter net product revenues from Jakafi, reflecting solid growth in underlying demand Top-line results from Phase II trial of ruxolitinib in patients with refractory metastatic pancreatic cancer suggest a demonstrable survival benefit in a well-defined subgroup of patients Positive Phase II data from trials of oral JAK1 inhibitor, INCB39110, in psoriasis and rheumatoid arthritis presente... 
Printer Friendly Version
October 28, 2013Positive Results Presented from Proof-of-Concept Phase II Clinical Trial of Incyte’s Oral JAK1 Inhibitor in Patients with Active Rheumatoid Arthritis
In results presented at the 2013 ACR/ARHP Annual Scientific Meeting, INCB39110 improved multiple rheumatoid arthritis efficacy scores as compared to placebo over 12 weeks of therapy INCB39110 was generally well-tolerated without evidence of myelosuppression or immunosuppression SAN DIEGO--(BUSINESS WIRE)--Oct. 28, 2013-- Incyte Corporation (Nasdaq: INCY) announced results from a 12-week, placebo-controlled, dose-escalation Phase II proof-of-concept clinical trial involving 60 patients with a... 
Printer Friendly Version
October 10, 2013Incyte to Report Third Quarter 2013 Financial Results on October 31
WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 10, 2013-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its third quarter conference call for 8:30 a.m. ET on Thursday, October 31, 2013. The schedules for the press release and conference call are as follows:       -- Q3 2013 Press Release:   ... 
Printer Friendly Version
October 03, 2013Positive Results Presented from Proof-of-Concept Phase II Clinical Trial of Incyte’s Oral JAK1 Inhibitor in Patients with Chronic Plaque Psoriasis
In data presented at EADV, treatment with INCB39110 achieved efficacy in multiple psoriasis severity measures as compared to placebo over four weeks of therapy INCB39110 was generally well-tolerated, with no evidence of myelosuppression ISTANBUL--(BUSINESS WIRE)--Oct. 3, 2013-- Incyte Corporation (Nasdaq: INCY) announced results from a 28-day, placebo-controlled, dose-escalation Phase II proof-of-concept clinica... 
Printer Friendly Version
September 03, 2013Incyte to Ring NASDAQ Stock Market Opening Bell in Support of Blood Cancer Awareness Month
Live Webcast Available Starting at 9:15 am ET Incyte Launches ‘Voices of MPN’ Initiative to Unite, Connect and Support Community Affected by Rare Blood Cancers: Myeloproliferative Neoplasms (MPNs) WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 3, 2013-- Incyte Corporation (Nasdaq:INCY) will ring the opening bell at the NASDAQ MarketSite today to support the start of Blood Cancer Awareness Month and the launch of Voices o... 
Printer Friendly Version
September 03, 2013New ‘Voices of MPN’ Initiative Unites, Connects and Supports Community Affected by Rare Blood Cancers: Myeloproliferative Neoplasms (MPNs)
In Connection with Blood Cancer Awareness Month in September, Incyte Launches Community Awareness Program September 12 Designated as Inaugural MPN Awareness Day WILMINGTON, Del – September 3, 2013 – September is Blood Cancer Awareness Month, and it is estimated that nearly 300,000 people in the United States are living with myeloproliferative neoplasms (MPNs), a group of closely related blood cancers that includes myelofibrosis, polycythemia vera and essential thrombocythemia. People impact... 
Printer Friendly Version
August 28, 2013Incyte to Present at the Morgan Stanley Global Healthcare Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 28, 2013-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11 at 1:30 p.m. (EDT) in New York. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available. Investors interested in listening to the live ... 
Printer Friendly Version
August 21, 2013Incyte Provides Top-Line Results from Phase II Proof-of-Concept Trial of Ruxolitinib in Patients with Refractory Metastatic Pancreatic Cancer
Overall survival analysis demonstrated a hazard ratio of 0.79 and a pre-specified subgroup analysis achieved a significant benefit with a hazard ratio of 0.47 Results expected to define and support a pivotal registration program in metastatic pancreatic cancer WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 21, 2013-- Incyte Corporation (Nasdaq: INCY) announced top-line results of the Phase II, randomized, double-blind,... 
Printer Friendly Version
August 05, 2013Incyte to Present at the Canaccord Genuity 33rd Annual Growth Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 5, 2013-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the Canaccord Genuity 33rd Annual Growth Conference on Wednesday, August 14 at 10:30 a.m. (EDT) in Boston. The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available. Investors interested in listening to the live w... 
Printer Friendly Version
August 01, 2013Incyte Reports Second-Quarter 2013 Financial Results; Increases Revenue Guidance; Updates Shareholders on Key Clinical Programs
$54.1 million of second-quarter net product revenues from Jakafi, reflecting solid growth in underlying demand 2013 guidance for Jakafi net product revenues increased to range of $220 million to $230 million New data presented for Jakafi suggest an impact on bone marrow fibrosis and provide further evidence of a survival advantage in myelofibrosis patients New dosing guidance for myelof... 
Printer Friendly Version
July 11, 2013Incyte to Report Second Quarter 2013 Financial Results on August 1
WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 11, 2013-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its second quarter conference call for 8:30 a.m. ET on Thursday, August 1, 2013. The schedules for the press release and conference call are as follows:       -- Q2 2013 Press Release:   ... 
Printer Friendly Version
June 16, 2013Incyte Drug Jakafi® (ruxolitinib) Improved Overall Survival in Phase III Trial of Patients with Myelofibrosis
New three-year COMFORT-II study data presented at the European Hematology Association (EHA) meeting show that patients treated with Jakafi experienced sustained reductions in spleen size and a 52 percent reduction in the risk of death relative to patients treated with best available therapy COMFORT-II data also show that Jakafi continues to be well-tolerated after three years of treatment Results from ... 
Printer Friendly Version
June 13, 2013Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis
- Results from 52-week study presented at EULAR 2013 - MADRID, June 13, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) today announced 52-week efficacy and safety data from the open-label, long-term extension of the Phase 2b JADA study of baricitinib in patients with active rheumatoid arthritis (RA). Baricitinib, formerly LY3009104 (INCB28050), is an orally available Janus kinase (JAK) inhibitor being studied for use in the treatment of certain ... 
Printer Friendly Version
June 12, 2013Jakafi® (ruxolitinib) Prescribing Information Updated with Expanded Dosing Guidance and New Safety Information
WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 12, 2013-- Incyte Corporation (Nasdaq: INCY) announced today that the U.S. Food and Drug Administration (FDA) has updated prescribing information for Jakafi® (ruxolitinib) to include new recommended dosing guidance for patients with low platelet counts and additional safety information. Approved in November 2011, Jakafi is the first and only FDA-approved product for the treatment of patients with intermediate or hi... 
Printer Friendly Version
June 04, 2013Data Presented at 2013 ASCO Offers First Evidence that Long-Term Treatment with Jakafi® (ruxolitinib) May Stabilize or Reverse Bone Marrow Fibrosis, a Key Marker of Worsening Disease in Patients with Myelofibrosis
CHICAGO--(BUSINESS WIRE)--Jun. 4, 2013-- Incyte Corporation (Nasdaq: INCY) announced that results from an exploratory analysis of bone marrow fibrosis data from an ongoing Phase I/II single-arm, open-label clinical trial for Jakafi® (ruxolitinib) were presented today at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Fibrosis of the bone marrow, a cardinal feature of myelofibrosis (MF), was shown to stabilize or re... 
Printer Friendly Version
June 01, 2013Incyte Presents Final Results from a Phase I Trial of INCB024360, a Novel Oral Immunotherapy, at ASCO
Data demonstrate that INCB024360 achieves greater than 90 percent inhibition of IDO1 at generally well-tolerated doses and may represent a new treatment option for advanced malignancies Data suggest the potential for INCB024360 to be used as monotherapy or in combination with other cancer agents CHICAGO--(BUSINESS WIRE)--Jun. 1, 2013-- Incyte Corporation (Nasdaq: INCY) presented final results today from the Phas... 
Printer Friendly Version
May 22, 2013Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--May. 22, 2013-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of June: Jefferies 2013 Global Healthcare Conference on Thursday, June 6, 2013 at 12:30 pm (EDT) in New York; Goldman Sachs 34th Annual Global Healthcare Conference on Tuesday, June 11, 2013 at 3:20 pm (PDT) / 6:20 pm (EDT) in Rancho Palo... 
Printer Friendly Version
May 03, 2013Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--May. 3, 2013-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of May: Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013 at 2:20 pm (PDT) / 5:20 pm (EDT) in Las Vegas; and 2013 UBS Global Healthcare Conference on Monday, May 20, 2013 at 2:30 pm (EDT) in New York ... 
Printer Friendly Version
May 02, 2013Incyte Reports First-Quarter 2013 Financial Results; Updates Shareholders on Key Clinical Programs
- $48.3 million of first-quarter 2013 net product revenues from Jakafi® (ruxolitinib) Conference Call Scheduled Today at 8:30 a.m. ET WILMINGTON, Del.--(BUSINESS WIRE)--May. 2, 2013-- Incyte Corporation (Nasdaq: INCY) today reported first-quarter 2013 financial results, including revenue from Jakafi® (ruxolitinib), which is approved by the U.S. Food & Drug Administration (FDA) for the treatment of patients with intermediate or high... 
Printer Friendly Version
April 29, 2013Incyte Achieves $25 Million Milestone as c-MET Inhibitor INC280 Advances Into Phase II Development
WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 29, 2013-- Incyte Corporation (NASDAQ: INCY) announced today that it has earned a $25.0 million milestone payment from Novartis based on the formal initiation of a Phase II clinical trial evaluating c-MET inhibitor INC280 (formerly INCB28060) as monotherapy in patients with advanced hepatocellular carcinoma. The Phase II trial is being conducted by Novartis as part of a Collaboration and License Agreement, in which... 
Printer Friendly Version
April 11, 2013Incyte to Report First Quarter 2013 Financial Results on May 2
WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 11, 2013-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its first quarter conference call for 8:30 a.m. ET on Thursday, May 2, 2013. The schedules for the press release and conference call are as follows:               -- Q1 2013 Press Release: May 2, 2013 at 7:00 a.m. ET -- Q1 2013 Conference Call: May 2, 2013 at 8:30 a.m. ET -... 
Printer Friendly Version
February 20, 2013Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 20, 2013-- Incyte Corporation (Nasdaq:INCY) announced today it will present at the following investor conferences during the month of March: Cowen and Company’s 33rd Annual Health Care Conference on Wednesday, March 6, 2013 at 11:20 a.m. (ET) in Boston. Barclays Capital Global Healthcare Conference on Wednesday, March 13, 2013 at 9:00 a.m. (ET) in Miami. ... 
Printer Friendly Version
February 14, 2013Incyte Reports 2012 Fourth-Quarter and Full-Year Financial Results; Provides 2013 Financial Guidance; Updates Shareholders on Key Clinical Programs
$43.3 million of fourth-quarter and $136.0 million of full-year 2012 net product revenues from Jakafi® (ruxolitinib) Net product revenue guidance for 2013 in the range of $210 million to $225 million $50 million milestone earned from Eli Lilly for initiation of Phase III clinical program for baricitinib in rheumatoid arthritis Conference Call Scheduled Today at 8:30 a.m. ET ... 
Printer Friendly Version
January 24, 2013Incyte to Report Fourth Quarter/Year-End 2012 Financial Results on February 14
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 24, 2013-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its fourth quarter/year-end 2012 financial results conference call for 8:30 a.m. ET on Thursday, February 14, 2013. The schedules for the press release and conference call are as follows:       ... 
Printer Friendly Version